explore -WSS

explore

author：hotspot 2025-08-12 09:13:12 - browse：96

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： People with mental disorders often marry others with same

WSS

Humans aren't the only ones with an imagination. Rats have it too

Trial using CRISPR to edit HIV out of cells disappoints

Key Senate panel to consider PBM, drug pricing reform package

What is microchimerism and how does it affect maternal health?

Researchers test human milk's ability to repair gut microbiome

Readout LOUD podcast: ESMO highlights & Roivant's big deal

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

entertainment

Hollywood unions extend contract negotiations for actors

Scientific mystery highlights the blind spots in genomics databases

The high cost of giving birth even with insurance

How to convince healthy people to buy insurance

State Dept. review finds Biden bears some blame for Afghanistan failures

Inari Medical to buy amputation prevention company LimFlow

New air purifier tech could be key to improving indoor air quality

Harvard scientists, with Google, unveil the most detailed brain map ever

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

entertainment

Medicare must police algorithms in Medicare Advantage, Dems say

How neuroscience research could help beat back brain cancer

Pancreatic cancer is often deadly, but new discoveries are raising hope

Travis Kelce and the trap of celebrity vaccine endorsements

Mass General Brigham physicians react to latest merger step

Coloradans with cystic fibrosis could lose access to Trikafta

focus

knowledge

focus

leisure time